The Robust MiYOSMART Evidence Portfolio Boosted by Promising One-Year Results from a European Cohort


Bangkok, Thailand – HOYA Vision Care, committed to developing innovative solutions to address the growing problem of myopia progression in children, extended its research to Europe in an effort to battle this problem globally.

In the eye care industry, most research on childhood myopia is being conducted in East Asia, where the condition is most prevalent.(1) However, due to the prevalence of myopia increasing worldwide, there is also a need to test effectiveness of myopia management solutions in children of other ethnicities and geographical areas.(1) That’s why the HOYA Global Medical Affairs  team is conducting a 3-year observational study in the United Kingdom (UK), eager to extend the reach of MiYOSMART benefits to European children with myopia. This new study reached its 1-year milestone early this year, the results of which were officially presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 conference on the 23rd-27th of April, in New Orleans.(2)

The study involves 128 children aged 5 to 15 recruited at  three university  centres in the UK. All children were prescribed MiYOSMART spectacle lenses and their progress was followed, with the aim to evaluate the performance of MiYOSMART spectacle lenses in European children.(2) The results of the study demonstrated similar effectiveness of MiYOSMART spectacle lenses in Caucasian versus Asian children, particularly in children aged 8 to 13 years .(2,3) Most children were symptom-free within one week, showing great tolerability and acceptance.(2)

“We are very excited to share the encouraging interim results of our European research so far. Childhood myopia is a widespread concern, and we are committed to continue fighting this problem, by using innovative solutions like MiYOSMART spectacle lenses. The comparable results in the European cohort signal to us that MiYOSMART is an effective way to slow myopia progression in children across the globe with different ethnicities. We look forward to sharing the full results from this 3-year study in the near future”, said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care.

HOYA Vision Care is committed to evidence-based myopia management, and strives to bring this approach to the next level by empowering Eye Care Professionals in their clinical practice. They action this commitment through their new Confidence through Evidence campaign, which was launched on the 1st of October, 2023. The campaign aims to educate Eye Care Professionals on the importance of evidence in childhood myopia, as well as bring attention to the robust MiYOSMART evidence, which will allow Eye Care Professionals  to confidently manage myopia in their everyday clinical practice.

“It’s important to choose treatments to slow the progression of myopia in children based on best evidence available”, said Professor Saw Seang Mei from Singapore Eye Research Institute, in one of the campaign expert interviews published by HOYA Vision Care on the social media portal, LinkedIn.

Over 2 million parents across the world have already trusted MiYOSMART, since its launch in 2018.(4) With the MiYOSMART evidence extending to European cohort, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world. 


1. Grzybowski A, Kanclerz P, Tsubota K, Lanca C, Saw SM. A review on the epidemiology of myopia in school children worldwide. BMC Ophthalmol. 2020;20(1):27.

2. McCullough S, Barr, H, Fulton, J, et al. 2-Year Multi-Site Observational Study of MiYOSMART myopia control spectacle lenses in UK children:1-year results (Abstract). ARVO 2023; 23-27 April 2023; New Orleans, LA, USA.

3. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-8.

4. Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of July 2023.